Modification by bradykinin B2 receptor blockade of protection by pacing against ischaemia-induced arrhythmias

European Journal of Pharmacology

Volumn 328, Issue 1, 1997, Pages 51-60

  Kaszala, Károly ^a   Végh, Ágnes ^a   Papp, Julius Gy ^a   Parratt, James R ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bradykinin; Cardiac pacing; Icatibant; Ischemic preconditioning; Rapid; Ventricular arrhythmia

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; ICATIBANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ RECEPTOR; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART RATE; ISCHEMIC PRECONDITIONING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ARRHYTHMIA; BLOOD PRESSURE; BRADYKININ; CARDIAC PACING, ARTIFICIAL; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEART RATE; ISCHEMIC PRECONDITIONING; MALE; MYOCARDIAL ISCHEMIA; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; VENTRICULAR FUNCTION, LEFT;

EID: 0030608764     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)83027-0     Document Type: Article

References (36)

1. Calixto J.B., Madeiros Y.S. Bradykinin-induced biphasic response in the rat isolated stomach fundus: functional evidence for a novel bradykinin receptor. Life Sci. 50:1992;47-53.
2. 1 receptor. Br. J. Pharmacol. 108:1993;318-322.
3. Cohen, M.V., Liu, Y., Downey, J.M., 1996. Activation of protein kinase C is critical to the protection of preconditioning. In: Wainwright, C.L., Parratt, J.R. (Eds.), Myocardial Preconditioning. Springer, Heidelberg, pp. 185-206.
4. Gho, B.C.G., Koning, M.M.G., Opstal, R.L.J., Van Klaarwater, E., Duncker, D.J., Verdouw, P.D., 1996. Novel approaches to myocardial preconditioning in pigs. In: Wainwright, C.L., Parratt, J.R. (Eds.), Myocardial Preconditioning. Springer, Heidelberg, pp. 97-113.
5. Hartman J.C., Wall T.M., Hullinger T.M., Shebuski R.J. Reduction of myocardial infarct size in rabbits by ramiprilat; reversal by the bradykinin antagonist HOE 140. J. Cardiovasc. Pharmacol. 21:1993;996-1003.
6. Hecker M., Porsti I., Bara A., Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br. J. Pharmacol. 111:1994;238-244.
7. Kaszala K., Végh Á., Parratt J.R., Papp J.Gy. Time course of pacing-induced preconditioning in dogs. J. Mol. Cell. Cardiol. 27:1995;A145.
8. Kaszala K., Végh Á., Papp J.Gy., Parratt J.R. Time course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing. J. Mol. Cell. Cardiol. 28:1996;2085-2095.
9. Kimura E., Hashimoto K., Furukawa S., Hawakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am. Heart J. 85:1973;635-647.
10. Linz W., Schölkens B.A. Specific B2-bradykinin receptor antagonist HOE-140 abolishes antihypertrophic effect of ramipril. Br. J. Pharmacol. 105:1992;771-772.
11. Linz W., Martorana P.A., Grotsch H., Bei-Yin Q., Scholkens B.A. Antagonising bradykinin (BK) obliterates the cardioprotective effects of bradykinin and angiotensin-converting enzyme (ACE) inhibitors in ischemic hearts. Drug Dev. Res. 19:1990;393-408.
12. Marshall R.J., Parratt J.R. The early consequences of myocardial ischaemia and their modification. J. Physiol. (Paris). 76:1980;699-715.
13. Martorana P.A., Kettenbach B., Breipohl G., Linz W., Scholkens B.A. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur. J. Pharmacol. 182:1990;395-396.
14. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia; a delay of lethal cell injury in ischemic myocardium. Circulation. 74:1986;1124-1136.
15. Murray A., Heistad D.D., Mayhan W.G. Role of protein kinase C in bradykinin-induced increases in microvascular permeability. Circ. Res. 68:1991;1340-1345.
16. Parratt J.R. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc. Res. 27:1993;693-702.
17. Parratt J.R., Végh Á. Endothelial cells, nitric oxide and ischaemic preconditioning. Basic Res. Cardiol. 91:1996;27-30.
18. Parratt J.R., Végh Á., Papp J.Gy. Bradykinin as an endogenous myocardial protective substance with particular reference to ischaemic preconditioning - a brief review of the evidence. Can. J. Physiol. Pharmacol. 73:1995;837-842.
19. Parratt J.R., Végh Á., Kaszala K., Papp J.Gy. Protection by preconditioning and cardiac pacing against ventricular arrhythmias resulting from ischaemia and reperfusion. Ann. NY Acad. Sci. 793:1996;98-107.
20. Parratt, J.R., Végh, Á., Zeitlin, I.J., Ahmed, M., Oldroyd, K., Kaszala, K., Papp, J.Gy., 1997. Bradykinin and endothelial-cardiac myocyte interactions in ischaemic preconditioning. Am. J. Cardiol. (in press).
21. Pitt B., Mason J., Conti C.R., Colman R.W. Activation of the plasma kallikrein system during myocardial ischaemia. Adv. Exp. Med. Biol. 8:1970;343-347.
22. Rösen P., Eckle J., Reinauer H. Influence of bradykinin on glucose uptake and metabolism studied in isolated cardiac myocytes and isolated perfused rat hearts. Hoppe-Seylers Z. Physiol. Chem. 364:1983;1431-1438.
23. Scherf H., Pietsch R., Landsberg G., Kramer H.J., Dusing R.et al. Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism. Klin. Wochenschr. 64:1986;742-745.
24. Sharma A.D., Corr P.B. Adrenergic factors in arrhythmogenesis in the ischaemic and reperfused myocardium. Eur. Heart J. 4(Suppl. d):1983;79-83.
25. Végh Á., Szekeres L., Udvary É. Effect of the blood supply to the normal noninfarcted myocardium on the incidence and severity of early post-occlusion arrhythmias in dogs. Basic Res. Cardiol. 82:1987;159-171.
26. Végh Á., Szekeres L., Parratt J.R. Protective effects of preconditioning on the ischaemic myocardium involves cyclooxygenase products. Cardiovasc. Res. 24:1990;1020-1023.
27. Végh Á., Szekeres L., Parratt J.R. Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning. Cardiovasc. Res. 25:1991;1051-1053.
28. Végh Á., Szekeres L., Parratt J.R. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetised dogs. Br. J. Pharmacol. 104:1991;294-295.
29. Végh Á., Komori S., Szekeres L., Parratt J.R. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc. Res. 26:1992;487-495.
30. Végh Á., Szekeres L., Parratt J.R. Preconditioning of the ischaemic myocardium: involvement of the L-arginine nitric oxide pathway. Br. J. Pharmacol. 107:1992;648-652.
31. Végh Á., Papp J.Gy., Szekeres L., Parratt J.R. Prevention by an inhibitor of the L-arginine nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs. Br. J. Pharmacol. 110:1993;18-19.
32. 2 receptors. Br. J. Pharmacol. 113:1994;1167-1172.
33. Wainwright, C.L. and Parratt, J.R., 1996. Myocardial Preconditioning, Heidelberg, Springer.
34. Wall T.M., Sheehy R., Hartman J.C. Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. 270:1994;681-689.
35. Wall T.M., Linseman D.A., Hartman J.C. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism. Eur. J. Pharmacol. 306:1996;165-174.
36. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., Henke S., Breiphol G., Konig W., Knolle J., Scholkens B.A. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102:1991;774-777.